Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth ...

If Eli Lilly ... new pill is designed to mimic the glucagon-like peptide 1 hormone that our bodies produce naturally, albeit in very small, transient doses. In earlier phase two trials the company ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon ... make up the base foundation of the building. And then another company comes in and ties into the framing and ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli ... new area for Lilly, and one that is ripe for disruption given the size of the addressable market. I think the company ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another ... Novo Nordisk announces new early clinical trial data for ...